Press releases

Regulatory press release 2021-07-28

Xspray Pharma announces achievement of bioequivalence compared with reference product from bioequivalence study with HyNap-Dasa 505(b)(2)

Press release 2021-06-28

All participants in Xspray Pharma’s study have received their dose of the improved version of dasatinib

Press release 2021-06-23

Xspray Pharma’s two incentive programs are fully subscribed

Press release 2021-06-10

Xspray Pharma commences study with improved version of dasatinib

Regulatory press release 2021-05-20

Bulletin from the annual general meeting of Xspray Pharma AB (publ)

All press releases

Latest report
Interim Report Q1 2021
Subscribe
Get our latest press releases and reports
Subscribe
Submit to our press releases and get an email every time we publish a press release or report on our website.
Type*
Reports
Press releases
E-mail*

Välj språk*
Swedish
English
When clicked on Send I agree that my personal information will be saved. Read more
Email
This field is for validation purposes and should be left unchanged.

Press contact

Per Andersson, CEO

+46 (0)8 730 37 00

per.andersson@xspray.com

Presentations and interviews

Presentation at Redeye Growth Day, June 2, 2021

Presentation of Xspray Pharma at Redeye Orphan Drug Seminar, April 28, 2020

Interview with Per Andersson at Redeye, April 9, 2021

Media